Alebai U. Sabitov

Alebai U. Sabitov

Auto-generated profile, based on publicly available information

Alebai U. Sabitov

Ural State Medical University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2021 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
ASAlebay U. Sabitov
Alebay U. Sabitov
PSPavel V. Sorokin
Pavel V. Sorokin
SDSvetlana Yu. Dashutina
Svetlana Yu. Dashutina
Aim. The assessment of the effectiveness, safety and tolerance of the drug Riamilovir for emergency drug prevention in the foci of a new coronavirus infection (COVID-19). Materials and methods. The trial included 113 persons aged 18 years and older who had level 1 contacts with patients with a new coronavirus infection (COVID-19), who had not previously been ill, with negative PCR results for COVID-19. Results. The high effectiveness, safety and good tolerance of the preventive use of the drug Riamilovir for the period of 20 days of taking a prophylactic dose of 1 capsule (250 mg) per day in the foci of COVID-19 has been established. Conclusion. The effectiveness and safety of the preventive use of the drug Riamilovir allow to recommend it for emergency drug prophylaxis in contact persons in the foci of a new coronavirus infection (COVID-19).

30 August 2021 in Antibiot Khimioter = Antibiotics and Chemotherapy
Verified
Journal Article
Closed access
PDF file
ASA. U. Sabitov
A. U. Sabitov
OKO. P. Kovtun
O. P. Kovtun
NBN. A. Batskalevich
N. A. Batskalevich
OMO. V. Maltsev
O. V. Maltsev
KZK. V. Zhdanov
K. V. Zhdanov
ASA. V. Stepanov
A. V. Stepanov
The aimof the study was to carry out meta-analysis of randomized controlled trials in order to combine the results of clinical trials on Triazavirin®(Riamilovir) efficacy in the etiotropic therapy of acute respiratory viral infection.Materials and methods.The studies included 435 patients with a confirmed diagnosis of acute respiratory viral infection or ARVI (with laboratory confirmed absence of influenza virus antigens). The research was carried out in 27 centers. In studies, patients were divided into 3 groups in a 1:1:1 ratio (a total of 145 people per group). Each study included a group taking 100 mg of the medication 5 times a day, a group taking 250 mg of the medication 3 times a day and a placebo 2 times a day, as well as a group taking a placebo 5 times a day. The analysis was carried out in accordance with the PRISMA principles regarding the quality of information presentation on the results of systematic reviews and meta-analyzes of works evaluating the effects of medical interventions.Results. The conducted meta-analysis showed that the use of Triazavirin®(Riamilovir) has a statistically significantly effects on the severity of clinical symptoms in patients with ARVI. The performed meta-analysis confirmed reliable associations between the use of Triazavirin®(Riamilovir) in both doses and the chance of a persistent improvement in clinical symptoms on the 5thday of therapy. The meta-analysis also confirmed the statistical significance of the clinical effects of Riamilovir by such indicators as the area under the curve «point on the scale showing the severity of the condition in a patient with ARVI in relation to time», the proportion of patients with complete alleviation of all symptoms by the end of the 5th day from the start of therapy.Conclusion.The clinical trials proved that the use of Triazavirin®(Riamilovir) is effective both in the initial and in the late stages of the disease, therefore, the drug can be used in the initial therapy of adult patients with respiratory diseases of viral etiology.

6 May 2021 in Antibiot Khimioter = Antibiotics and Chemotherapy
Verified
Journal Article
Closed access
PDF file
АSА. U. Sabitov
А. U. Sabitov
РSР. V. Sorokin
Р. V. Sorokin
SDS. U. Dashutina
S. U. Dashutina
CДC. Ю. Дашутина
C. Ю. Дашутина
Aim. Evaluation of the efficacy, safety, and tolerability of Riamilovir (trade name «Triazavirin®») in patients with mild COVID-19.Materials and methods. The randomized open-label study included 120 patients with clinical and epidemiological manifestations of coronavirus infection and its laboratory (PCR) confirmation.Results. The efficacy, safety, as well as good tolerability of Riamilovir in the treatment of new coronavirus infection (COVID-19) have been established.Conclusion. The results of the study on the efficacy, safety, and tolerability of Riamilovir allow us to recommend it as a means of etiotropic therapy of the new coronavirus infection (COVID-19).

30 August 2021 in Antibiot Khimioter = Antibiotics and Chemotherapy
Verified
Journal Article
Closed access
PDF file
ASA. U. Sabitov
A. U. Sabitov
OKO. P. Kovtun
O. P. Kovtun
NBN. A. Batskalevich
N. A. Batskalevich
НЛН. И. Львов
Н. И. Львов
KZK. V. Zhdanov
K. V. Zhdanov
ASA. V. Stepanov
A. V. Stepanov
The aim of the study was to carry out a meta-analysis of randomized clinical trials in order to combine the results of clinical trials on Triazavirin® (Riamilovir) efficacy in etiotropic therapy of influenza.Materials and methods. The analysis was carried out in accordance with the PRISMA principles regarding the quality of information presentation on the results of systematic reviews and meta-analyzes of works assessing medical interventions. The study included 471 patients with a confirmed diagnosis of influenza (with laboratory confirmed presence of influenza virus antigens).Results. The conducted meta-analysis showed that the use of Triazavirin® (Riamilovir) has a statistically significant effect on the severity of clinical symptoms in patients with influenza, therefore Riamilovir can be used in the initial therapy of adult patients with influenza.Conclusion. Clinical studies have shown that the use of Triazavirin® (Riamilovir) is effective both in the initial and late stages of the disease, and therefore Riamilovir can be used in the treatment of adult patients with respiratory diseases of viral etiology, in particular, those diagnosed with influenza. The meta-analysis of the collected data showed that therapy with Triazavirin® (Riamilovir) has statistically significant advantages in various aspects both in comparison with the placebo group and with the Tamiflu® (Oseltamivir) group.

16 April 2024 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
ASAlebai U. Sabitov
Alebai U. Sabitov
DLDmitry Lioznov
Dmitry Lioznov
KZKonstantin V. Zhdanov
Konstantin V. Zhdanov
ETElena P. Tihonova
Elena P. Tihonova
EEElena V. Esaulenko
Elena V. Esaulenko
PSPavel V. Sorokin
Pavel V. Sorokin
Aim. Evaluation of the efficacy and safety of riamilovir as a drug for the prevention of coronavirus infection (COVID-19) in adults who have constant contact with COVID-19 patients as a result of living together. Materials and methods. The study included 750 adult participants living with patients with confirmed polymerase chain reaction method COVID-19, who had a negative polymerase chain reaction result for the SARS-CoV-2 virus at the initial level, met the criteria for inclusion, non-inclusion and exclusion, and signed a voluntary informed consent to participate in a clinical trial. Results. The efficacy, good tolerability and safety of the drug riamilovir for the prevention of COVID-19 infection among people who have come into contact with COVID-19 patients in a family focus of infection have been established. Conclusion. As a result of a multicenter randomized double-blind clinical trial, the effectiveness of the drug riamilovir for the prevention of COVID-19 infection was established. It was shown that the relative risk of disease in the group taking riamilovir for prophylaxis was 88.96% lower than in the control group. Based on the results of a clinical trial, in October 2023 Ministry of Health of the Russian Federation approved the inclusion of a new indication (prophylaxis of COVID-19 infection) in the instructions for the medical use of the drug riamilovir (trade name – Triazavirin®).

3 June 2024 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
ASAlebai U. Sabitov
Alebai U. Sabitov
DLDmitry Lioznov
Dmitry Lioznov
KZKonstantin V. Zhdanov
Konstantin V. Zhdanov
ETElena P. Tikhonova
Elena P. Tikhonova
EEElena V. Esaulenko
Elena V. Esaulenko
PSPavel V. Sorokin
Pavel V. Sorokin
Aim. To evaluate the efficacy and safety of riamilovir in the treatment of COVID-19 in adults. Materials and methods. The study included 180 patients with a laboratory-confirmed diagnosis of COVID-19 which fully meet the criteria for inclusion, non-inclusion and exclusion, signed a voluntary informed consent to participate in a clinical trial. Results. The efficacy, good tolerability and safety of the drug riamilovir in the treatment of COVID-19 have been established. Conclusion. As a result of a multicenter randomized double-blind clinical trial, the effectiveness of the drug riamilovir for therapeutic use in patients with COVID-19 according to the 1250 mg/day scheme (250 mg capsules 5 times per day) for 10 days was established. The drug riamilovir in a daily dose of 1250 mg for 10 days does not differ in safety from placebo.